| Hazard Information | Back Directory | [Uses]
Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research[1][2]. | [in vivo]
Robatumumab (intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 d) inhibits the SK-N-FI tumor growth in xenograft model[2].
Robatumumab (intravenous injection; 0.02-0.5 mg/mouse; twice weekly; 35 d) inhibits the osteosarcoma growth in xenograft model[2].
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 d) inhibits the SJCRH30 and RD rhabdomyosarcoma cell growth in xenograft model[2].
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 w) blocks effectively pediatric tumor cell proliferation in vivo[2].
Robatumumab (intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation) modulates the blood vessel formation via its antiangiogenesis effect[2]. | Animal Model: | Nude mice inoculated with SK-N-FI tumor cells[2] | | Dosage: | 0.04 or 0.1 mg/mouse | | Administration: | Intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 days | | Result: | Inhibited the SK-N-FI xenograft tumor by 96% in the 0.04 mg dose group and resulted in 11% tumor regression in the 0.1 mg dose group. |
| Animal Model: | Nude mice inoculated with SJSA-1 osteosarcoma[2] | | Dosage: | 0.02, 0.1 or 0.5 mg/mouse | | Administration: | Intravenous injection; 0.02, 0.1 or 0.5 mg/mouse; twice weekly; 35 days | | Result: | Inhibited the tumor growth by 71%, 82%, and 88% at 0.02, 0.1, and 0.5 mg, respectively, at day 14 after treatment. |
| Animal Model: | Nude mice inoculated with SJCRH30 and RD rhabdomyosarcoma cells[2] | | Dosage: | 0.1 or 0.5 mg/mouse | | Administration: | Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 days | | Result: | Inhibited tumor growth by 39% and 58% at 0.1 and 0.5 mg dose, respectively, in the RD rhabdomyosarcoma model.
Inhibited tumor growth by 37% and 53% at 0.1 and 1 mg dose, respectively, in the SJCRH30 model. |
| Animal Model: | Nude mice inoculated with SK-N-FI neuroblastoma and SJSA-1 osteosarcoma[2] | | Dosage: | 0.1 or 0.5 mg/mouse | | Administration: | Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 weeks | | Result: | Reduced the tumor Ki-67 staining by 38% and along with significant change in SK-N-FI neuroblastoma xenograft.
Reduced the staining of Ki-67 by 37% and 51% after 0.1 and 0.5 mg SCH 717454 treatment, respectively, in the SJSA-1 osteosarcoma xenograft. |
| Animal Model: | Nude mice inoculated with SJSA-1 osteosarcoma[2] | | Dosage: | 0.5 mg/mouse | | Administration: | Intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation | | Result: | Reduced in the intensity of the fluorescent lectin staining by 74% at 0.5 mg dose, showing thinner blood vessels and reduced branches, compared with control IgG1. |
| [References]
[1] Anderson PM, et al. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. Pediatr Blood Cancer. 2016 Oct;63(10):1761-70. DOI:10.1002/pbc.26087
[2] Wang Y, et al. A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. Mol Cancer Ther. 2010 Feb;9(2):410-8. DOI:10.1158/1535-7163.MCT-09-0555 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|